Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Enbrel Copycat Next Biosimilar To Get Panel Treatment

Executive Summary

The FDA has elected to take Sandoz Inc.'s 351(k) application for its etanercept biosimilar, which is referenced on Amgen Inc.'s tumor necrosis factor blocker Enbrel, to an advisory committee to get its advice on whether to license the product. It's only the third biosimilar to get the expert panel treatment.

Advertisement

Related Content

Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts
Lawsuit: Sandoz Copycat Piggybacks Enbrel, Ducks Duties
Panel Favors Celltrion Biosimilar; Skeptical On Cost Savings
US Capitol Capsule: Don't Make Assumptions On Biosimilars Actions, FDA Official Warns
FDA's 1st biosimilar adcomm: a lovefest

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC065385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel